echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > CRISPR gene editing to knock out PD-1 improved ready-to-use CAR-T therapy enters clinical trials

    CRISPR gene editing to knock out PD-1 improved ready-to-use CAR-T therapy enters clinical trials

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Caribou Biosciences, a CRISPR genome-editing biomedical company, announced that the company’s innovative allogeneic CAR-T therapy CB-010 is used in the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL).


    CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells


    The usual CRISPR gene editing system uses guide RNA (guide RNA) to mediate the cleavage of specific sites in the genome by the Cas enzyme


    Note: The original text has been deleted

    Reference materials:

    [1] Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.